Nanohale AG (FYB) | WebDisclosure

Basculer en Français

8209	Companies
109627	Keywords
51715	Articles
60337	Press releases

Home
Companies
Nanohale AG

PRESS RELEASE

published on 04/12/2024 at 19:27, 6 months 22 days ago

EQS-Adhoc: Formycon AG publishes preliminary figures for the 2023 financial year and guidance for the 2024 financial year
Formycon AG publishes preliminary figures for 2023 financial year and guidance for 2024. EBITDA expected around EUR 1.5 million for 2023 and revenues of EUR 55-65 million for 2024

EBITDA 2023 Financial Year Formycon AG Preliminary Figures 2024 Financial Year
BRIEF

published on 04/11/2024 at 07:35, 6 months 24 days ago

Formycon and Bioeq Launch FYB201 in Canada and Switzerland

Biosimilar Formycon Bioeq FYB201 AMD Treatment
BRIEF

published on 04/11/2024 at 07:35, 6 months 24 days ago

Formycon et Bioeq lancent FYB201 au Canada et en Suisse

Formycon Bioeq EFB201 Traitement De La DMLA Biosimilaire
PRESS RELEASE

published on 04/11/2024 at 07:30, 6 months 24 days ago

Formycon announces commercial launch of FYB201 (Ranibizumab) in Canada (RanoptoTM) and Switzerland (Ranivisio®)
Formycon announces commercial launch of FYB201 (Ranibizumab) in Canada and Switzerland, expanding availability in 17 countries. Biosimilar offers cost-effective treatment for retinal diseases

Ranibizumab Biosimilar Formycon FYB201 Commercial Launch
BRIEF

published on 03/18/2024 at 10:05, 7 months 18 days ago

Formycon and Fresenius Kabi Reach Settlement with Johnson & Johnson for FYB202 in Europe and Canada

Biosimilars Settlement Agreement Formycon Fresenius Kabi FYB202
BRIEF

published on 03/18/2024 at 10:05, 7 months 18 days ago

Formycon et Fresenius Kabi parviennent à un accord avec Johnson & Johnson pour FYB202 en Europe et au Canada

Formycon Fresenius Kabi FYB202 Entente De Règlement Biosimilaires
PRESS RELEASE

published on 03/18/2024 at 10:00, 7 months 18 days ago

Formycon and Fresenius Kabi reach settlement agreement for ustekinumab biosimilar candidate FYB202 in Europe and Canada
Formycon and Fresenius Kabi reach settlement agreement with Johnson & Johnson for ustekinumab biosimilar FYB202 in Europe and Canada. Agreement terms kept confidential. Focus on expanding patient access and ensuring reliable treatment options

Settlement Agreement Biosimilar Formycon Fresenius Kabi Ustekinumab
BRIEF

published on 03/11/2024 at 07:35, 7 months 25 days ago

FYB201/Ranibizumab Gains Approval and Scheduled for Launch in the MENA Region

MENA Region Formycon AG MS Pharma Ranibizumab Diabetic Retinopathies
BRIEF

published on 03/11/2024 at 07:35, 7 months 25 days ago

FYB201/Ranibizumab obtient l'approbation et son lancement est prévu dans la région MENA

Formycon AG MS Pharma Ranibizumab Région MENA Rétinopathies Diabétiques
PRESS RELEASE

published on 03/11/2024 at 07:30, 7 months 25 days ago

FYB201/Ranibizumab keeps gaining momentum with approvals and launches in the MENA region
Formycon AG and MS Pharma announce the approval and market launch of FYB201/Ranibizumab in the MENA region, with plans for commercialization in Saudi Arabia and other countries in 2024

MENA Region Formycon AG MS Pharma FYB201/Ranibizumab Biosimilar

Accesswire

Published on 11/05/2024 at 09:15, 2 hours 43 minutes ago

Troy Minerals Targets Restart of Drilling at Tsagaan Zalaa
Published on 11/05/2024 at 09:05, 2 hours 53 minutes ago

Omega Pacific Adds John Williamson as Independent Director
Published on 11/05/2024 at 08:00, 3 hours 58 minutes ago

Touchstone Exploration Announces Execution of Licence for Rio Claro Block
Published on 11/05/2024 at 08:00, 3 hours 58 minutes ago

Argo Blockchain PLC Announces October Operational Update
Published on 11/05/2024 at 03:30, 8 hours 28 minutes ago

CORRECTION: Savencia Cheese USA Announces Voluntary Recall of Select Soft Ripened Cheeses

View all ACCESSWIRE

EQS Group

Published on 11/05/2024 at 11:13, 44 minutes ago

Circus Secures EUR 1.1 Billion in recurring Revenue Potential and Expands Its AI Capabilities
Published on 11/05/2024 at 11:13, 45 minutes ago

Elmos: Positive closing of the third quarter of 2024 and confirmation of the sales and EBIT outlook for 2024 – Announcement of midterm financial targets 2030
Published on 11/05/2024 at 10:59, 58 minutes ago

EQS-Adhoc: Elmos Semiconductor SE announces midterm financial targets 2030
Published on 11/05/2024 at 10:50, 1 hour 7 minutes ago

Holding(s) in Company
Published on 11/05/2024 at 10:50, 1 hour 8 minutes ago

Morocco Showcase Summit dévoile les opportunités de tourisme et d’investissement

Les Echos

Published on 11/05/2024 at 09:58, 1 hour 59 minutes ago

ENGIE - déclaration mensuelle du nombre total d'actions et de droits de vote composant le capital au 31 octobre 2024
Published on 11/05/2024 at 09:27, 2 hours 30 minutes ago

Mersen: Number of shares and voting rights as of October 31, 2024
Published on 11/05/2024 at 09:27, 2 hours 30 minutes ago

Mersen : nombre d'actions et de droits de vote au 31 octobre 2024
Published on 11/05/2024 at 08:30, 3 hours 28 minutes ago

Cie du Bois Sauvage: Terugkoop van eigen aandelen – Week van 28/10/2024 tot 01/11/2024
Published on 11/05/2024 at 08:30, 3 hours 28 minutes ago

Cie du Bois Sauvage : Rachat d’actions propres – semaine du 28/10/2024 au 01/11/2024

View all LES ECHOS COMFI WIRE